chartexchange

Zydus Lifesciences Faces 5 US FDA Observations at Moraiya Plant; Could US Sales Be at Risk?

Trade Brains | Oct 26, 2026 6:39 AM EDT

Compliance is one of the most important factors in the pharmaceutical industry, especially for companies that are highly exposed to the US market. The recent observations by the US FDA at the Moraiya facility of Zydus Lifesciences have led to questions about manufacturing, quality control, and the impact on US sales.
With a market capitalisation of Rs. 1,15,211 cr, the shares of Zydus Lifesciences Ltd were trading at Rs. 1155 per share, up from its previous close of Rs. 1,127.85 per share. The stock jumped 14% in the last year, 26% year-to-date, 23% in the last six months, and 5% down in the past month. 

Also Read: Sensex & Nifty 50 | Stock Market Highlights 26 Oct 2026: Sensex Rises 483 Points, Nifty Gains 0.68%; Metals, Infrastructure and Pharma Lead

Overview of the US FDA Inspection
Zydus Lifesciences Ltd has been given five observations by the US Food and Drug Administration (FDA) after inspecting its Moraiya manufacturing unit located in Gujarat between October 5 and October 13, 2026. The observations include issues related to laboratory records, quality investigations, raw materials testing, and manufacturing processes.
The development is important since the Moraiya manufacturing plant has been claimed to contribute roughly 45% of Zydus Lifesciences' US sales. It may affect the company’s US business if there are any consequences for its manufacturing process, product approval, or supply. Nevertheless, the five observations do not necessarily mean that there will be a shutdown of manufacturing at the factory or a ban on exports to the US.
Data Integrity and Laboratory Documentation
Another observation relates to the lack of microbial growth observed in routine testing in the laboratory. Proper documentation in the laboratory is vital in proving that the pharmaceutical products being manufactured are in line with the quality requirements before their release to the market.
There was also no documented performance verification for three years for Fourier-transform infrared (FTIR) used in raw material identification according to the FDA. The lack of documentation for the verification process over the three-year period is a cause for concern regarding the integrity of the testing process at the facility.
Quality-Control Investigations and Product Safety
The regulator had issues related to inadequate investigation into the presence of metal shavings in a tablet. This is linked to the earlier Class II product recall involving the same product. In such cases, it is necessary to conduct comprehensive investigations into how the problem occurred, to understand the risks involved, and take preventive action to avoid future problems.

Also Read: KEI Industries: 35% Below Its 52-Week High After Q2 Results Disappoint - Is the Correction a Buying Opportunity or a Warning Sign?

The FDA also noted that there were several batches of drugs that exceeded assay control limits but did not undergo root cause investigations before release. Assay testing is done to determine the quantity of the active ingredient in a drug.
Raw-Material Testing and Compliance Procedures
Another concern involved the reduction of incoming raw-material testing despite earlier failures to meet specifications. Pharmaceutical manufacturers must ensure that raw materials comply with quality requirements, particularly when previous test results have indicated potential problems.
Also Read: 
The inspection also identified a lack of written procedures for identifying, investigating and reporting suspected or illegitimate drug products. Such procedures are important for detecting potentially fraudulent medicines and maintaining compliance with US pharmaceutical regulations. Zydus may need to strengthen its standard operating procedures, documentation practices and employee training to address these observations.
Why the Observations Matter for US Sales
It is especially significant because of the contribution made by the Moraiya site to Zydus Lifesciences US sales, estimated at about 45%. For Indian pharma firms, the US is a crucial market, and compliance with regulations is a crucial aspect of business continuation and ensuring the supply of goods.
While satisfying all the observations raised would not bring any immediate consequences from a commercial point of view, problems of compliance in case of prolonged non-compliance or additional actions from the FDA can put the production and supplies from the site at risk.
What Investors Should Monitor
Investors should monitor any official response from Zydus Lifesciences, the corrective and preventive actions undertaken at the Moraiya facility, and any subsequent communication from the US FDA. Further regulatory developments, including restrictions on manufacturing or product supplies, would be more consequential than the observations alone.

Also Read: Ramky Infrastructure bags ₹588.57 Cr EPC contract from RVNL for NMDC township residential project in Chhattisgarh

Importantly, five FDA observations do not by themselves establish that the facility has failed an overall inspection or that US sales will decline. The financial implications will depend on the severity of the deficiencies, the company's response and whether the regulator takes further action.

Read original article